1Department of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
2Department of Neurosurgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
3Department of Radiology and Research Institute of Radiology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
© The Korean Society of Pathologists/The Korean Society for Cytopathology
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Study | No. of cases | Age (yr) | Sex (M:F) | Locations | Outcomes |
---|---|---|---|---|---|
Le Loarer et al. (2020) [7] | 14 | 11–86 (mean, 31) | 3:4 | Craniofacial (8/14), other bone (4/14), soft tissue (2/12) | Median survival: 8 months |
Chrisinger et al. (2020) [19] | 23a | 11–86 | 1:2.7 | Craniofacial (12/23), other bone (9/23), soft tissue (2/23) | Median survival: 15 months |
Xu et al. (2021) [18] | 27a | 11–74 (mean, 25) | 1.25:1 | Craniofacial (18/27), other bone (8/27), soft tissue (1/27) | 1- and 2-year disease-specific survival rate: 74% and 35%, respectively |
Dehner et al. (2023) [6] | 56a | 8–86 (mean, 34) | 5:9 | Craniofacial (37/56), other bone (13/56), soft tissue (6/56) | Median survival: 21 months |
Ethics Statement
This study was approved by the Institutional Review Board, and the need for informed consent was waived (Asan Medical Center IRB No. 2023-1548).
Availability of Data and Material
The datasets generated or analyzed during the study are available from the corresponding author on reasonable request.
Code Availability
Not applicable.
Author Contributions
Conceptualization: JSS. Data curation: HRA. Investigation: HRA, JSS. Resources: SWS, JEP, JSS. Supervision: JSS, KJC. Visualization: HRA, JSS. Writing—original draft preparation: HRA. Writing—review & editing: KJC, SWS, JEP, JSS. Approval of final manuscript: all authors.
Conflicts of Interest
J.S.S., a contributing editor of the Journal of Pathology and Translational Medicine, was not involved in the editorial evaluation or decision to publish this article. All remaining authors have declared no conflicts of interest.
Funding Statement
No funding to declare.
Study | No. of cases | Age (yr) | Sex (M:F) | Locations | Outcomes |
---|---|---|---|---|---|
Le Loarer et al. (2020) [7] | 14 | 11–86 (mean, 31) | 3:4 | Craniofacial (8/14), other bone (4/14), soft tissue (2/12) | Median survival: 8 months |
Chrisinger et al. (2020) [19] | 23a | 11–86 | 1:2.7 | Craniofacial (12/23), other bone (9/23), soft tissue (2/23) | Median survival: 15 months |
Xu et al. (2021) [18] | 27a | 11–74 (mean, 25) | 1.25:1 | Craniofacial (18/27), other bone (8/27), soft tissue (1/27) | 1- and 2-year disease-specific survival rate: 74% and 35%, respectively |
Dehner et al. (2023) [6] | 56a | 8–86 (mean, 34) | 5:9 | Craniofacial (37/56), other bone (13/56), soft tissue (6/56) | Median survival: 21 months |
Study | No. of cases | Age (yr) | Sex (M:F) | Locations | Outcomes |
---|---|---|---|---|---|
Le Loarer et al. (2020) [7] | 14 | 11–86 (mean, 31) | 3:4 | Craniofacial (8/14), other bone (4/14), soft tissue (2/12) | Median survival: 8 months |
Chrisinger et al. (2020) [19] | 23 |
11–86 | 1:2.7 | Craniofacial (12/23), other bone (9/23), soft tissue (2/23) | Median survival: 15 months |
Xu et al. (2021) [18] | 27 |
11–74 (mean, 25) | 1.25:1 | Craniofacial (18/27), other bone (8/27), soft tissue (1/27) | 1- and 2-year disease-specific survival rate: 74% and 35%, respectively |
Dehner et al. (2023) [6] | 56 |
8–86 (mean, 34) | 5:9 | Craniofacial (37/56), other bone (13/56), soft tissue (6/56) | Median survival: 21 months |
This number includes data from previously reported cases through a literature review.